A co‐IP assay in CD133+ glioma cells expressing CD133 shRNA and either shRNA‐resistant wild‐type CD133 or its deletion mutant, further showed that the CD133(1–862) mutant lacking a region between residues 863 and 865 could not interact with DNMT1 (Figure S1I, Supporting Information). Here, DNMT1 is linked to central nervous system cancer.